The Global Burden of Diabetes and the Economic Imperative for Prevention

Diabetes mellitus, predominantly type 2 diabetes, has reached epidemic proportions worldwide. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a number projected to rise to 783 million by 2045. The disease imposes a staggering economic burden: global health spending on diabetes was estimated at USD 966 billion in 2021, representing a 316% increase over the past 15 years. Beyond direct medical costs, diabetes contributes to lost productivity, disability, and premature mortality. These figures underscore the urgent need for effective prevention strategies that are not only clinically sound but also economically sustainable.

The concept of cost-effectiveness in healthcare compares the relative costs and outcomes (health effects) of different interventions. For diabetes, early identification of at-risk individuals through risk testing, followed by evidence-based preventive measures, has been shown to be highly cost-effective, and in many settings, cost-saving. Understanding this cost-effectiveness landscape is essential for healthcare payers, policymakers, and providers who must allocate limited resources to maximize population health.

Defining the Target: Type 2 Diabetes Risk Factors and Natural History

Before examining the economics, it is critical to understand whom we are testing and why. Type 2 diabetes typically develops over years or decades, progressing through stages of insulin resistance and beta-cell dysfunction. Individuals with prediabetes—defined by impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or an elevated hemoglobin A1c between 5.7% and 6.4%—are at high risk. Without intervention, approximately 5-10% of people with prediabetes progress to diabetes annually.

Key Risk Factors for Type 2 Diabetes

  • Overweight or obesity (body mass index ≥ 25 kg/m², especially with central adiposity)
  • Family history of diabetes (first-degree relative)
  • Physical inactivity (sedentary lifestyle)
  • Unhealthy diet (high in processed foods, sugar, and saturated fats)
  • Age ≥ 45 years (risk increases with age)
  • History of gestational diabetes or giving birth to a baby weighing >9 pounds
  • High blood pressure (≥140/90 mmHg) or on antihypertensive therapy
  • Ethnicity (higher risk in African American, Hispanic, Native American, Asian American, and Pacific Islander populations)
  • Polycystic ovary syndrome (PCOS) and other insulin-resistant conditions

Risk testing identifies individuals who possess these factors and stratifies them by their likelihood of developing diabetes within a defined timeframe (e.g., 5–10 years).

Methods of Diabetes Risk Testing: Tools, Accuracy, and Costs

A variety of risk assessment tools exist, ranging from simple, self-administered questionnaires to blood-based laboratory tests. The choice of method influences both the cost of screening and the accuracy of identifying true high-risk individuals.

Non-Invasive Risk Scores

Examples include the Finnish Diabetes Risk Score (FINDRISC), the American Diabetes Association (ADA) Risk Test, and the Indian Diabetes Risk Score. These questionnaires use easily obtainable data (age, BMI, family history, physical activity, dietary habits) to assign a risk score. They are inexpensive to administer and can be widely deployed in community settings, pharmacies, or online portals. However, their sensitivity and specificity vary; a meta-analysis found that FINDRISC (cutoff ≥12) had a sensitivity of 77% and specificity of 66% for detecting prediabetes.

Blood-Based Tests

  • Fasting Plasma Glucose (FPG): Measures blood glucose after an 8-hour fast. Cost per test is low (typically < $10 in most settings). Identifies IFG if 100–125 mg/dL.
  • Hemoglobin A1c (HbA1c): Reflects average blood glucose over 2–3 months. No fasting required. Cutoff for prediabetes: 5.7%–6.4%. Slightly higher cost than FPG but more convenient.
  • Oral Glucose Tolerance Test (OGTT): Measures glucose before and 2 hours after a 75g glucose load. Gold standard for diagnosing IGT. More expensive, time-consuming, and burdensome for patients.

Many cost-effectiveness models use a hybrid approach: initial screening with a risk score, followed by confirmatory blood testing for those identified as high-risk. This two-step strategy balances upfront costs against the need for accurate case-finding.

The Evidence Base for Diabetes Prevention: Landmark Trials

Prevention programs aim to reduce the incidence of diabetes among high-risk individuals. The economic value of these programs depends heavily on their efficacy and durability. Three landmark randomized controlled trials provide the bedrock of evidence:

1. The Diabetes Prevention Program (DPP) – United States

Enrolling over 3,000 adults with IGT and elevated fasting glucose, the DPP compared a lifestyle intervention (intensive diet and exercise, goal of 7% weight loss), metformin (850 mg twice daily), and placebo. Results showed a 58% reduction in diabetes incidence with lifestyle and a 31% reduction with metformin over 3 years. Long-term follow-up (DPP Outcomes Study) demonstrated that these benefits persist for at least 15 years, with lifestyle retaining a 27% risk reduction.

2. The Finnish Diabetes Prevention Study (DPS)

A similar trial involving 522 overweight subjects with IGT. The lifestyle intervention (diet, exercise) reduced diabetes risk by 58% over 4 years, consistent with the DPP. Follow-up at 13 years showed sustained risk reduction of 43%.

3. The Da Qing Diabetes Prevention Study – China

This quasi-experimental study of 577 adults with IGT tested diet, exercise, or both. Over 6 years, diabetes incidence was reduced by 31–46% in the intervention groups. Remarkably, 30-year follow-up data showed reduced cardiovascular mortality and a 45% lower incidence of diabetes in the lifestyle groups.

These trials demonstrate that lifestyle intervention (and in some cases, metformin) can dramatically reduce diabetes onset. Subsequent real-world translation programs, such as the National Diabetes Prevention Program (NDPP) in the U.S., have shown that scaled-up delivery can maintain effectiveness, though with slightly attenuated results (25-30% risk reduction) in pragmatic settings.

Frameworks for Cost-Effectiveness Analysis in Diabetes Prevention

Cost-effectiveness analyses (CEAs) quantify the ratio of incremental costs to incremental health benefits. The standard metric is the incremental cost-effectiveness ratio (ICER), typically expressed as cost per quality-adjusted life year (QALY) gained. An intervention is generally considered cost-effective if its ICER falls below a willingness-to-pay (WTP) threshold (e.g., $50,000–$100,000 per QALY in the U.S.; £20,000–£30,000 per QALY in the UK). Some analyses also report cost per diabetes case averted or life-years gained.

Key inputs for any CEA of diabetes prevention include:

  • Cost of screening and confirmatory testing
  • Cost of the prevention program (e.g., lifestyle coach, materials, participant time)
  • Effectiveness of prevention in reducing diabetes incidence
  • Long-term costs of diabetes management (including complications)
  • Changes in quality of life (avoiding diabetes complications)
  • Discount rate (typically 3% annually) for costs and effects occurring in future years

Review of Key Cost-Effectiveness Studies

A substantial body of literature supports the cost-effectiveness of diabetes risk testing plus prevention.

Lifestyle Intervention vs. Standard Care

A 2017 systematic review by the UK National Institute for Health and Care Excellence (NICE) evaluated multiple CEAs of lifestyle-based diabetes prevention. The ICERs for lifestyle intervention ranged from approximately £6,000 to £27,000 per QALY gained, well below the typical NICE threshold of £20,000–£30,000. The DPP lifestyle intervention in the U.S. was estimated to cost about $1,200 per participant per year, yielding an ICER of $12,000 per QALY over a lifetime horizon. Even when accounting for program costs and participant time, the lifestyle intervention consistently emerged as cost-effective, and in many scenarios cost-saving (i.e., lower overall healthcare costs) within 10–15 years.

Metformin for Prevention

Metformin is substantially cheaper than lifestyle programs (approximately $50–$300 per year for medication plus monitoring). CEAs generally find metformin to be cost-effective, though often less so than lifestyle because of its lower efficacy. The ICER for metformin was estimated at $14,000–$18,000 per QALY in the DPP analysis. However, metformin may be more cost-effective than lifestyle in resource-limited settings or for individuals who cannot adhere to intensive behavioral programs.

Screening Strategies

The cost-effectiveness of screening itself depends on the target population and screening method. Targeted screening of high-risk groups (e.g., overweight adults aged 45+) is more efficient than universal screening. A U.S. modeling study found that screening with the ADA Risk Test followed by HbA1c testing had an ICER of $15,000 per QALY among adults aged 45–75. Screening younger adults (25–44) was also cost-effective if they had additional risk factors. Opportunistic screening in primary care settings (e.g., during routine visits) further reduces implementation costs.

Real-World Translation Programs

Analysis of the U.S. National DPP found that it cost approximately $400–$600 per participant per year to deliver through organizations like YMCAs and online platforms. The ICER was estimated at $16,000 per QALY, assuming a 24% relative risk reduction. A 2021 study projected that widespread implementation of the National DPP could prevent over 330,000 cases of diabetes and save $2.1 billion in healthcare costs over 5 years. Another analysis from the CDC showed that every dollar invested in the program saved approximately $1.50 in medical costs within 3 years.

Factors Influencing Cost-Effectiveness

Time Horizon

Short-term analyses (1–3 years) often show higher costs and modest health gains, making interventions appear less attractive. However, over a lifetime horizon, the prevention of diabetes and its complications (cardiovascular disease, kidney failure, amputation, blindness) generates substantial health benefits and cost savings. Most CEAs use a minimum 10-year horizon, with lifetime models being preferred.

Population Risk Level

Interventions are more cost-effective in populations with higher baseline diabetes risk. A key reason for screening is to identify those at highest risk, maximizing the absolute risk reduction per unit cost. For example, targeting individuals with IGT plus obesity yields far better cost-effectiveness ratios than targeting young, lean individuals with no family history.

Intervention Intensity and Delivery Mode

Group-based programs, online coaching, and community health worker-delivered programs can be less expensive per participant than one-on-one in-person counseling, while maintaining reasonable effectiveness. A 2020 meta-analysis of 22 economic evaluations found that group-based lifestyle interventions had a median ICER of $9,800 per QALY, compared to $17,400 per QALY for individual counseling. Digital interventions (mobile apps, telehealth) show promise for further reducing delivery costs.

Healthcare System Context

The cost-effectiveness threshold varies by country. In low- and middle-income countries (LMICs), where per-capita healthcare spending is lower, interventions must be very inexpensive. The WHO has set a threshold of 1-3 times gross domestic product (GDP) per capita per QALY. Fortunately, low-cost interventions such as metformin, community-based lifestyle education, and simplified screening scores (e.g., the Indian Diabetes Risk Score) have been shown to be cost-effective in LMICs. A study from India estimated that screening and lifestyle intervention cost INR 45,000–60,000 per QALY gained, well under India's GDP per capita.

Challenges to Implementation and Real-World Cost-Effectiveness

While the academic evidence strongly supports cost-effectiveness, real-world implementation faces several hurdles that can erode economic value.

Uptake and Adherence

Screening programs require high uptake to be effective. Many at-risk individuals do not attend screening appointments. Once enrolled, adherence to prevention programs is variable. The DPP had excellent adherence (over 90% of sessions attended), but translation programs often see lower retention. Participants who drop out do not benefit, and their screening costs become wasted. Strategies to improve engagement—such as financial incentives, text reminders, and community support—can add cost but may improve overall cost-effectiveness if they boost retention.

Limited Access to Care

In rural or underserved areas, access to quality preventive services may be limited. Lack of nearby labs for blood testing, shortage of trained lifestyle coaches, and cultural barriers reduce the feasibility of implementing evidence-based programs. Telemedicine and mobile health units can partially mitigate these issues but require upfront investment.

Resource Allocation Trade-offs

Health systems with constrained budgets must choose between multiple priorities. Even cost-effective interventions may be underfunded if they require upfront expenditure that generates savings only years later. Policymakers may favor interventions with faster returns (e.g., cancer screening, vaccination) over long-term prevention. This tension is partly addressed by value-based payment models and public health campaign framing that emphasizes long-term health and economic impacts.

Diagnostic Criteria and Labeling

The diagnosis of prediabetes is controversial due to different glycemic thresholds among organizations (ADA, WHO, International Expert Committee). Using a lower cutoff (e.g., HbA1c ≥ 5.5%) increases sensitivity but also increases false positives, leading to unnecessary interventions and costs. A higher cutoff may miss many high-risk individuals. The optimal screening strategy balances sensitivity and specificity to maximize cost-effectiveness.

Policy Implications and Recommendations

Based on the evidence, several policy actions can enhance the cost-effectiveness of diabetes risk testing and prevention on a population level.

  1. Integrate risk testing into routine primary care. The ADA recommends universal testing for all adults aged 45 and older, with earlier testing for those with risk factors. This opportunistic approach avoids the need for separate screening campaigns and reduces marginal costs.
  2. Adopt a stepped-care approach. Use simple risk scores as a first pass, then confirm high-risk individuals with blood tests. This reduces the number of expensive tests required.
  3. Invest in scalable, low-cost lifestyle interventions. Support digital health platforms, community health worker programs, and group-based classes that can be deployed at low per-participant cost. Certification and reimbursement mechanisms (like Medicare coverage of the National DPP in the U.S.) encourage program fidelity and sustainability.
  4. Combine prevention with chronic disease management. Embed diabetes prevention programs within existing infrastructure for managing hypertension, obesity, or cardiovascular risk. This leverages shared resources and patient populations.
  5. Incorporate value-based pricing for preventive medications. Metformin is inexpensive, but newer diabetes drugs (GLP-1 receptor agonists) are being studied for prevention. Their high cost currently makes them not cost-effective for prevention compared to lifestyle. Pricing should reflect the value in preventing diabetes.
  6. Use health economic modeling to tailor local strategies. Because cost-effectiveness depends on population demographics, risk distribution, and local costs, each health system should run its own models to identify the optimum screening age, risk threshold, and intervention mix.

Future Directions: Emerging Technologies and Evolving Economics

The landscape of diabetes prevention is evolving rapidly, which may further improve cost-effectiveness or introduce new challenges.

Artificial Intelligence and Risk Prediction

Machine learning models that incorporate electronic health record data, genetic risk scores, and continuous glucose monitoring can identify high-risk individuals with greater precision. If these models reduce false positives and unnecessary interventions, they could lower screening costs. However, the cost of developing and implementing such algorithms needs to be weighed against incremental benefits.

Personalized Prevention

Tailoring prevention intensity to an individual's risk profile—e.g., digital coaching for low-risk, intensive lifestyle for high-risk—could allocate resources efficiently. Ongoing trials like the PRE-POD study are exploring this approach, and early economic models suggest favorable ICERs.

Implementation in Low- and Middle-Income Countries

As prevalence rises most rapidly in LMICs, cost-effective adaptations of Western prevention models are needed. Innovations such as community-based screening using mobile vans, simplified lifestyle messages, and culturally tailored dietary advice have shown promise. The WHO's HEARTS technical package and the Global Diabetes Compact provide frameworks for scaling up. The cost per person screened can be as low as $1–2 using risk scores, making nationwide screening feasible even in resource-constrained settings.

Conclusion

The question is no longer whether diabetes risk testing and prevention are cost-effective—the evidence overwhelmingly says they are. The challenge is translating this evidence into widespread, sustainable practice. Landmark trials such as the DPP and Da Qing study provide indisputable proof that lifestyle and metformin reduce diabetes incidence, and economic analyses consistently find these interventions to be good value for money, often cost-saving in the long term. By integrating screening into routine care, implementing scalable prevention programs, and continually refining approaches based on local data and emerging technologies, health systems can reduce the human and economic toll of diabetes. The investment required today pales in comparison to the costs of inaction.